{
    "symbol": "NVCN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-12 23:00:03",
    "content": " Total expenses for the 3 months ended March 31, 2022 was $7.1 million compared to $10.6 million for 2021, representing a decrease of $3.5 million, or 33%, substantially explained by one, a $1.6 million decrease in legal and underwriting fees related to the February 2021 financing; two, a $1.3 million decrease in non-cash share-based payments due to an adjustment in the expected life of the share appreciation plan and due to voluntary forfeit of certain incentive options by certain employees; and three, a $1 million decrease in employee expenses and other product development and clinical trial expenses as we definitely paused all activities related to the Tiara TF, a transfemoral mitral valve replacement program in June 2021. The operating losses and comprehensive losses for the 3 months ended March 31, 2022 was $6.6 million and $10.4 million respectively or $3.75 basic and diluted loss per share as compared with $10.1 million operating losses and $2.9 million comprehensive losses or $1.11 basic and diluted share \u2013 loss per share for the same period in 2021."
}